Humacyte Inc (NASDAQ: HUMA) on Friday, plunged -2.97% from the previous trading day, before settling in for the closing price of $4.72. Within the past 52 weeks, HUMA’s price has moved between $2.81 and $9.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -26.30%. With a float of $104.39 million, this company’s outstanding shares have now reached $119.84 million.
Let’s look at the performance matrix of the company that is accounted for 183 employees. In terms of profitability, gross margin is 35.2%, operating margin of -1042.56%, and the pretax margin is -1416.75%.
Humacyte Inc (HUMA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Humacyte Inc is 18.86%, while institutional ownership is 28.23%. The most recent insider transaction that took place on Dec 04 ’24, was worth 20,181. In this transaction Director of this company bought 4,600 shares at a rate of $4.39, taking the stock ownership to the 16,950 shares. Before that another transaction happened on Nov 19 ’24, when Company’s President, CEO and Director bought 1,797 for $4.44, making the entire transaction worth $7,979. This insider now owns 243,851 shares in total.
Humacyte Inc (HUMA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -26.30% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Humacyte Inc (HUMA) is currently performing well based on its current performance indicators. A quick ratio of 1.10 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Humacyte Inc (NASDAQ: HUMA) saw its 5-day average volume 1.54 million, a negative change from its year-to-date volume of 2.55 million. As of the previous 9 days, the stock’s Stochastic %D was 57.47%. Additionally, its Average True Range was 0.37.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 35.59%, which indicates a significant decrease from 67.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.15% in the past 14 days, which was lower than the 95.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.51, while its 200-day Moving Average is $5.63. Nevertheless, the first resistance level for the watch stands at $4.79 in the near term. At $4.99, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.14. If the price goes on to break the first support level at $4.44, it is likely to go to the next support level at $4.29. Assuming the price breaks the second support level, the third support level stands at $4.09.
Humacyte Inc (NASDAQ: HUMA) Key Stats
Market capitalization of the company is 589.30 million based on 125,859K outstanding shares. Right now, sales total 0 K and income totals -110,780 K. The company made 0 K in profit during its latest quarter, and -39,200 K in sales during its previous quarter.
